- Home
- NWSA vs INCY Comparison
NWSA vs INCY Comparison
Compare NWSA & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWSA
- INCY
- Stock Information
- Founded
- NWSA 2012
- INCY 1991
- Country
- NWSA United States
- INCY United States
- Employees
- NWSA N/A
- INCY N/A
- Industry
- NWSA Newspapers/Magazines
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- NWSA Consumer Discretionary
- INCY Health Care
- Exchange
- NWSA Nasdaq
- INCY Nasdaq
- Market Cap
- NWSA 15.7B
- INCY 13.4B
- IPO Year
- NWSA N/A
- INCY 1993
- Fundamental
- Price
- NWSA $28.35
- INCY $68.46
- Analyst Decision
- NWSA Strong Buy
- INCY Hold
- Analyst Count
- NWSA 6
- INCY 20
- Target Price
- NWSA $38.80
- INCY $73.81
- AVG Volume (30 Days)
- NWSA 3.8M
- INCY 2.1M
- Earning Date
- NWSA 08-07-2025
- INCY 07-29-2025
- Dividend Yield
- NWSA 0.71%
- INCY N/A
- EPS Growth
- NWSA 136.22
- INCY N/A
- EPS
- NWSA 0.85
- INCY 0.10
- Revenue
- NWSA $10,268,000,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- NWSA N/A
- INCY $13.29
- Revenue Next Year
- NWSA $1.16
- INCY $10.47
- P/E Ratio
- NWSA $34.60
- INCY $623.03
- Revenue Growth
- NWSA 19.49
- INCY 17.13
- 52 Week Low
- NWSA $23.38
- INCY $53.56
- 52 Week High
- NWSA $30.69
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- NWSA 57.27
- INCY 56.95
- Support Level
- NWSA $27.25
- INCY $67.57
- Resistance Level
- NWSA $28.09
- INCY $71.29
- Average True Range (ATR)
- NWSA 0.42
- INCY 1.98
- MACD
- NWSA -0.00
- INCY -0.13
- Stochastic Oscillator
- NWSA 80.29
- INCY 61.55
About NWSA News Corporation
News Corporation is a diversified media conglomerate with significant presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.